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Introduction: Various techniques have been used in an attempt to achieve long-term
nipple projection following nipple-areolar reconstruction. A common setback, however,
is the diminution of projection overtime; this phenomenon is particularly evident fol-
lowing implant-based breast reconstruction. Artecoll may be suitable for injection into
the nipple complex to maintain permanent, 3-dimensional projection. Artecoll is an
injectable substance that is biocompatible and immunologically inert and resists degra-
dation in vivo. The purpose of this study was thus to prospectively evaluate the efficacy
of Artecoll (polymethylmethacrylate microspheres suspended in 3.5% denatured bovine
collagen with 0.3% lidocaine) in obtaining and maintaining nipple projection follow-
ing postmastectomy, nipple-areolar reconstruction. Methods: A prospective, clinical
trial was performed. Consecutive patients deemed to have inadequate nipple projection
at least 6 months following “C-V flap” or “modified-skate flap” reconstruction were
identified. Only women who had postmastectomy reconstruction with tissue expanders
and implants were considered eligible for participation. Artecoll was injected under the
nipple at 2 time points: baseline and 3 months. Calipers were used to measure nip-
ple projection preinjection and postinjection at baseline, 3, 6, and 9 months. Results:
Thirty-three nipples were injected in 23 patients. There were no adverse events. Prior to
injection, mean nipple projection was 1.33 ± 1.0 mm. The mean increase in projection
over the 9-month study period was both clinically and statistically significant (1.60 ±
1.24mm;P <. 001).Ahistoryofpriorirradiationwasasignificantnegativepredictorof
final nipple projection (P = .012). Conclusion: Artecoll injection is both feasible and
effective in increasing and maintaining nipple projection in the setting of implant-based
breast reconstruction.
This study was presented at the 61st Annual Meeting of the Canadian Society of Plastic Surgeons, Banff,
Alberta, Canada, May 2007.
Product support and research study assistant funding was provided, in part, by Canderm Pharma Inc
(Saint-Laurent, Canada) and Artes Medical (San Diego, Calif), respectively. Additional funding was obtained
through grant support, awarded by the Canadian Society of Plastic Surgeons’ Educational Foundation.
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By transforming the surgically created breast mound into a more natural-appearing
breast,nipple-areolarreconstructioncansignificantlyenhancepatients’perspectiveoftheir
overall aesthetic result and can improve patient satisfaction.1-3 The most challenging as-
pect of nipple reconstruction is, however, the creation of a 3-dimensional structure with
the dimensions and contour similar to a natural nipple. Various techniques have been used
in an attempt to achieve long-term nipple projection, including local skin flaps, cartilage
and fascial grafts, and nipple-sharing techniques. Irrespective of the technique used, a com-
mon disappointment is the loss of projection overtime.4-6 This phenomenon is particularly
evident following implant-based breast reconstruction.7
As a means to increase projection after nipple reconstruction, the subcutaneous in-
jection of Artecoll may be useful. Artecoll (Artes Medical, San Diego, Calif; Canderm
Pharma Inc, Saint-Laurent, Canada) is an injectable substance that consists of inert, non-
biodegradable poly(methyl methacrylate) microspheres suspended in a partially denatured
3.5% bovine collagen.8 After the subcutaneous injection of Artecoll, the collagen carrier
is degraded by the body within 3 months and completely replaced by a matrix of autoge-
nous collagen at a similar rate. Because the microspheres are nonbiodegradable and too
large to migrate to be phagocytosed by macrophages, tissue augmentation is expected to
be permanent.9-11 Thus, it is hypothesized that the subcutaneous injection of Artecoll will
provide long-lasting nipple projection with minimal patient morbidity and create a more
natural-looking breast following postmastectomy reconstruction.
The purpose of this study is thus to prospectively evaluate the efficacy of Artecoll
in augmenting and maintaining nipple projection in the setting of postmastectomy, implant
reconstruction.
METHODS
Aprospective,clinicaltrialwasdesigned.Formalapprovalbytheinstitutionalreviewboard
was obtained. Consecutive patients deemed to have inadequate nipple projection at least
6monthsfollowing“C-Vflap”or“modified-skateflap”reconstructionwereidentified.Only
women who have had postmastectomy reconstruction with tissue expanders and implants
were considered eligible for participation. Participants were excluded from participation if
they were younger than 21 years and had a known susceptibility to keloid formation and/or
a lidocaine, collagen, or dietary beef sensitivity.
Skintestingforcollagensensitivitywasperformedatleast1monthpriortostudyiniti-
ation. In the event of an adverse reaction, patients were excluded from further participation.
In all eligible patients, Artecoll was injected under the nipple at 2 time points: baseline and
3 ± 1 months. Injection with up to 2 syringes (1.4 mL) of Artecoll or injection to “tissue
tolerance” was performed at each time point. One clinician performed all of the injections.
Caliperswereusedtomeasurenippleprojectionpreinjectionandpostinjectionatbase-
line and 3 ± 1 months. Follow-up measurements were repeated at 6 ± 1 and 9 ± 1 months.
A single investigator was responsible for the performance of all caliper measurements.
Photographic documentation was similarly performed.
Sample size considerations
A priori sample size calculation was performed on the basis of the variance of paired
differencesobtainedfrompilotdata.12Todetectaclinicallysignificantincreaseinprojection
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(ie, an increase in nipple projection of 200% greater than baseline) with 90% power and a
significance level of 0.05, it was determined that 33 nipples were needed.
Statistical methods
Pairwise differences in projection were calculated using the Wilcoxon signed rank test.
Univariate and multivariate linear regression analyses were performed on all variables to
determine their influence on the efficacy of Artecoll injection. Statistical significance was
set at the 0.05 level. Stata statistical software was used (Stata Corp, College Station, Tex).
RESULTS
Thirty-three nipples were injected in 23 patients. Mean time from completion of nipple
reconstructionwas32.9±20.2months(range=7.28–66.07months).Meanvolumeinjected
at each time point was 0.55 ± 0.17 mL (range = 0.2–1.4 mL). There were no adverse
events. All patients tolerated the procedure without the need for additional local anesthesia.
Transient nipple swelling was noted immediately following injection.
Prior to injection, mean nipple projection was 1.33 ± 1.0 mm (range = 0.0–4.0 mm).
At 3 months postinjection, mean projection was 2.87 ± 1.8 mm (range = 0.0–6.0 mm). At
6 and 9 months, mean projection was 3.09 ± 1.6 mm (range = 0.0–6.0 mm) and 2.93 ±
1.49 mm, respectively (Fig 1).
The mean increase in projection over the 9-month study period was both clinically and
statisticallysignificant(1.60±1.24mm;range=−1.0–4.5mm)(P <. 001)(Figs2–4).The
mean increase in projection following the first injection (1.39 ± 1.55 mm; range =− 1.0–
4.0 mm; n = 31) was significantly higher than that following the second injection (0.43 ±
1.28 mm; range =− 2.0–4.0 mm; n = 27) (P = .0383). Mean final projection (9 months)
wassignificantlylowerinthesubsetofreconstructionsthatwerepreviouslyradiated(0.33±
0.98mm;range=0.0–4.0mm;n = 7)comparedwiththosethathadnohistoryofradiation
(1.90 ± 1.10 mm; range = 1.0–2.0 mm) (P = .005).
Figure 1. Mean nipple projection.
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Table 1. Univariate predictors of change in nipple projection following Artecoll
injection
Variable Coefﬁcient P
Prior history of radiation −1.558 .005
Time since nipple reconstruction, mo 0.010 .322
Baseline nipple projection −0.343 .127
Volume per injection, mL 2.839 .031
Total volume injected, mL 0.153 .812
Table 2. Multivariate predictors of change in
nipple projection following Artecoll injection
Variable Coefficient P
Prior history of radiation −1.350 .012
Volume per injection, mL 2.060 .094
The results of multivariate analysis similarly demonstrated that a history of prior chest
wall irradiation was a significant negative predictor of total increase in nipple projection
(P = .012). Conversely, baseline nipple projection, time since completion of nipple recon-
struction, and volume of Artecoll injected were not significant predictors of total nipple
projection achieved (Tables 1 and 2).
DISCUSSION
On the basis of the results of this study, it appears that the subcutaneous injection of
Artecoll is safe, feasible, and effective in increasing nipple projection after unsatisfactory
reconstructioninpatientswithbreastimplants.Thisobjectivedatacannowbeusedtoassist
patientsandsurgeonsalikeinevaluatingoptionswhenfacedwithdisappointingresultsafter
nipple reconstruction with local flaps. In addition, these measures can provide a baseline
for comparison following refinements in both surgical and nonoperative techniques.
It has been hypothesized that following nipple reconstruction with local skin flaps, the
lossofprojectionovertimeisduetotheabsenceofrigidconnectivetissuesupportand/orthe
imposition of centrifugal, wound contractile forces at the base of the reconstruction.13 By
injecting Artecoll into the subcutaneous tissues, however, support for the overlying dermal
envelope can be restored. Furthermore, while the injected collagen carrier in Artecoll is
degraded by the body within a period of 3 months, it is completely replaced by autogenous
collagenous tissue, which renders the results from injection long-lasting.
Perhaps not surprisingly, the results of our current study suggest that while the subcu-
taneous injection of Artecoll can be successfully performed, it appears to be less effective
in augmenting the nipple in the setting of prior radiotherapy. It is likely that any radiation-
induced skin changes would render the local skin flaps used to reconstruct the nipple less
pliable. It follows that the limited laxity of the taut dermal envelope would, in turn, restrict
the augmentation achieved through the injection of Artecoll.
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Figure 2. Baseline (a) right breast and (b) left breast.
Figure 3. Nine months following Artecoll injections at baseline and
3 months. Nipple areolar tattooing has been completed: (a) right breast and
(b) left breast.
These findings are consistent with those reported by Evans et al.13 Their group per-
formed a pilot study evaluating the use of a semipermanent soft-tissue filler, calcium
hydroxylapatite (Radiesse, Bioform Inc, San Mateo, CA), to maintain and/or restore pro-
jection in 6 breast-reconstruction patients. Injections were performed in all 6 patients, 1
year following autogenous tissue or combined autogenous tissue/implant reconstruction. A
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Figure 4. (a) Preoperative oblique view, (b) 9 months following Artecoll
injections at baseline and 3 months. Nipple areolar tattooing has been
completed, (c) closeup view of baseline nipple projection right breast,
(d) closeup anterioposterior view right breast at 9-month follow-up, and
(e) lateral view of right nipple.
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moderate improvement in nipple appearance postinjection was observed in the majority of
cases; yet, in reconstructed nipples with a tighter dermal envelope, the filler injected tended
to disperse into the areola creating a convexity to the areola without a discernible increase
in nipple projection.
While our current results suggest that the subcutaneous injection of Artecoll results in
bothasignificantandsustainedincreaseinnippleprojectioninthemajorityofpatientswho
have undergone prior implant-based reconstruction, these results are not generalizable to
those patients who have had autogenous tissue reconstruction. In fact, the results of a pilot
study performed by our group would suggest that the subcutaneous injection of Artecoll
produces neither a significant nor a sustained increase in nipple projection in this cohort of
patients. Future investigation may be warranted.
It is also important to note that the follow-up data in this current study are limited to
9 months following the first injection. Thus, to provide objective evidence of effectiveness
of this intervention over the lifetime of the patient, evaluation of the longer-term sustain-
ability of these results must be undertaken. Similarly, the impact of nipple projection on
postoperative patient satisfaction must be fully delineated. In breast surgery, the patient’s
perception of the impact of the reconstruction is the most significant outcome variable and
should be rigorously assessed in studies that attempt to evaluate surgical success. Future
clinical research should therefore include patient-reported outcome data, such as patient
satisfaction with improved nipple projection. Finally, as healthcare costs continue to esca-
late,thereisagrowingemphasisonevaluatingthecost-effectivenessofanintervention.The
high cost of soft-tissue fillers, such as Artecoll, underscores the need to rigorously evaluate
these outcomes. The availability of such information could then be used in combination
with the objective findings presented here to determine the overall cost utility of Artecoll
injections in the setting of unsatisfactory nipple reconstruction.
CONCLUSION
The subcutaneous injection of Artecoll results in a significant and sustained increase in
nipple projection following implant-based breast reconstruction.
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